Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

3
results for

"Hyun Phil Shin"

Article category

Keywords

Publication year

"Hyun Phil Shin"

Original Articles

Viral hepatitis

Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Hyun Phil Shin, Ji-Ae Park, Blaire Burman, Richard A. Kozarek, Asma Siddique
Clin Mol Hepatol 2017;23(4):316-322.
Published online August 22, 2017
DOI: https://doi.org/10.3350/cmh.2016.0087
Background/Aims
Treatment of chronic hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) is essential. The availability of sofosbuvir (SOF) has dramatically improved overall HCV cure rates, however there is insufficient data regarding its use in patients with CKD. We evaluated SOF in patients with hepatitis C genotype 1 (G1) and moderately impaired renal function.
Methods
We retrospectively reviewed all patients treated with a SOF-based regimen from December 2013 through September 2015 at Virginia Mason Medical Center. Data was then collected for HCV G1 patients with stage 3 CKD.
Results
A total of 28 patients with HCV G1 and stage 3 CKD were treated with a SOF-based regimen. Twenty-one patients had stage 3A CKD (estimated glomerular filtration rate [eGFR] 45–60 mL/min/1.73m2) and 7 patients had stage 3B CKD (eGFR 30–45 mL/min/1.73m2). The overall rate of sustained virologic response (SVR) 12 weeks after completion of therapy (SVR12) was 85.7% (24/28). SVR12 in stage 3A CKD patients was 81.0% (17/21) and in stage 3B CKD patients, SVR12 was 100% (7/7). Based on the treatment regimen used, the SVR12 was 81.8% (9/11), 92.3% (12/13), and 75.0% (3/4) for SOF/ledipasvir (LDV), SOF/simeprevir (SIM), and SOF/pegylated interferon (PEG)/ribavirin (RBV), respectively. Greater than 30% reduction eGFR was observed in 5 out of 28 patients.
Conclusions
SOF-based regimens resulted in high SVR12 rates in patients with moderately impaired renal function. During therapy, HCV patients with CKD should be carefully monitored for worsening renal function.

Citations

Citations to this article as recorded by  Crossref logo
  • Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir
    Hala Abd El Maguid, Ahmed Heiba, Enass El Sayed, Hazem El-Hariri, Haythem Tolba, Muhammad Abdel Ghaffar
    Open Access Macedonian Journal of Medical Sciences.2022; 10(B): 82.     CrossRef
  • Efficacy and safety of direct‐acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta‐analysis
    Jieun Lee, Sang Bong Ahn, Sun Young Yim, Jihyun An, Dae Won Jun, Min Jung Ko, Dong Ah Park, Jeong‐Ju Yoo
    Journal of Viral Hepatitis.2022; 29(7): 496.     CrossRef
  • Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients
    W. Fadili, A. Ait Errami, S. Zaoui, K. Elkassimi, N. ElBouhi, S. Oubaha, Z. Samlani, I. Laouad, K. Krati
    European Journal of Medical and Health Sciences.2021; 3(1): 160.     CrossRef
  • Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
    Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
    Nefrología.2020; 40(1): 46.     CrossRef
  • Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment
    Rasha Eletreby, Magdy El‐Serafy, Mahmoud Anees, Gamal Kasem, Marwa Salama, Reham Elkhouly, Mostafa Hamdy, Hisham Abdel Haleem, Ehab Kamal, Wael Abdel‐Razek, Rabab Salama, Mohamed Elshenawy, Ayman Shafeek, Mohamed Hassany, Manal H. El‐Sayed, Yehia El‐Shazl
    Liver International.2020; 40(4): 797.     CrossRef
  • Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease
    Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi
    Nefrología (English Edition).2020; 40(1): 46.     CrossRef
  • Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment
    Shao-Ming Chiu, Ming-Chao Tsai, Chun-Yen Lin, Chien-Hung Chen, Sheng-Nan Lu, Chao-Hung Hung, I-Shyan Sheen, Rong-Nan Chien, Chih-Lang Lin, Tsung-Hui Hu, Yu-Fan Cheng, Chao-Long Chen, Tatsuo Kanda
    PLOS ONE.2020; 15(4): e0231102.     CrossRef
  • Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
    Kazumichi Abe, Hiroto Wakabayashi, Haruo Nakayama, Tomohiro Suzuki, Masahito Kuroda, Naoe Yoshida, Jun Tojo, Atsuko Kogure, Tsuyoshi Rai, Hironobu Saito, Shinji Mukai, Masashi Fujita, Manabu Hayashi, Atsushi Takahashi, Hiromasa Ohira, Ming-Lung Yu
    PLOS ONE.2020; 15(12): e0243473.     CrossRef
  • Treating hepatitis C virus in dialysis patients: How, when, and why?
    Javier Pagan, Marco Ladino, David Roth
    Seminars in Dialysis.2019; 32(2): 152.     CrossRef
  • Sofosbuvir

    Reactions Weekly.2018; 1688(1): 219.     CrossRef
  • Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic
    Jessica L. Michal, Saira Rab, Manish Patel, Alison W. Kyle, Lesley S. Miller, Kirk A. Easley, Aley G. Kalapila
    AIDS Research and Human Retroviruses.2018; 34(8): 690.     CrossRef
  • Renal safety after one year of sofosbuvir‐based therapy for chronic hepatitis C: A Brazilian “real‐life” study
    T. Medeiros, N. F. Rosário, G. N. Saraiva, T. G. Andrade, A. A. Silva, J. R. Almeida
    Journal of Clinical Pharmacy and Therapeutics.2018; 43(5): 707.     CrossRef
  • 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

    Clinical and Molecular Hepatology.2018; 24(3): 169.     CrossRef
  • Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis
    Chih-Chin Kao, Yu-Shiuan Lin, Heng-Cheng Chu, Te-Chao Fang, Mai-Szu Wu, Yi-No Kang
    Journal of Clinical Medicine.2018; 7(10): 314.     CrossRef
  • Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir
    Josip Begovac, Juraj Krznarić, Nikolina Bogdanić, Loris Močibob, Šime Zekan
    Medicine.2018; 97(51): e13671.     CrossRef
  • Use of sofosbuvir in chronic kidney disease: Is it necessary?
    Tae Seop Lim, Sang Hoon Ahn
    Clinical and Molecular Hepatology.2017; 23(4): 308.     CrossRef
  • 10,226 View
  • 194 Download
  • 12 Web of Science
  • Crossref

Viral hepatitis

Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody
Chi Hoon Lee, Hyun Phil Shin, Joung Il Lee, Kwang Ro Joo, Jae Myung Cha, Jung Won Jeon, Jun Uk Lim, Joon Ki Min, Dong Hee Kim, Sung Wook Kang, Hyun Jun Joung
Clin Mol Hepatol 2013;19(4):376-381.
Published online December 28, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.4.376
Background/Aims

To identify the predicting factors of present hepatitis C virus (HCV) infection among patients with positivity for antibodies to HCV (anti-HCV).

Methods

We analyzed patients who showed positive enzyme immunoassay (EIA) results and performed an HCV RNA test as a confirmatory test at Kyung Hee University Hospital at Gangdong from June 2006 to July 2012. The features distinguishing the groups with positive and negative HCV RNA results were reviewed.

Results

In total, 490 patients were included. The results of the HCV RNA test were positive and negative in 228 and 262 patients, respectively. The index value of anti-HCV, mean age, platelet counts, total bilirubin, prothrombin time international normalized ratio, albumin and alanine transaminase (ALT) levels differed significantly between the two groups. On multivariable analysis, an index value of anti-HCV >10 [odds ratio (OR)=397.27, P<0.001), ALT >40 IU/L (OR=3.64, P=0.001), and albumin <3.8 g/dL (OR=2.66, P=0.014) were related to present HCV infection.

Conclusions

Although EIA is not a quantitative test, considering the anti-HCV titer with ALT and albumin levels may be helpful in predicting present of HCV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • A potential new way to facilitate HCV elimination: The prediction of viremia in anti-HCV seropositive patients using machine learning algorithms
    Tayibe Bal, Emre Dirican
    Arab Journal of Gastroenterology.2024; 25(2): 223.     CrossRef
  • The diagnostic significance of hepatitis C virus antibody levels for chronic hepatitis C virus infection
    Jin Gu Kang, Myoung Kuk Jang, Jung Hee Kim, Jang Han Jung, Ji Won Park, Sung Eun Kim, Sang Hoon Park, Myung Seok Lee, Ki Tae Suk, Dong Joon Kim, Hyoung Su Kim
    The Korean Journal of Internal Medicine.2023; 38(3): 362.     CrossRef
  • A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective
    Hye-Lin Kim, Kyung-Ah Kim, Gwang Hyun Choi, Eun Sun Jang, Moran Ki, Hwa Young Choi, Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2022; 28(1): 91.     CrossRef
  • Evaluation of Six Years of HCV Seroprevalance and Correlation with HCV RNA at a Tertiary Care Hospital
    Pınar Şamlıoğlu, Yeşer Karaca Derici, Güliz Doğan, Arzu Bayram, Sebahat Taş, Nisel Yılmaz
    The Journal of Tepecik Education and Research Hospital.2022; 32(2): 235.     CrossRef
  • Preliminary Evidence for a Relationship between Elevated Plasma TNFα and Smaller Subcortical White Matter Volume in HCV Infection Irrespective of HIV or AUD Comorbidity
    Natalie M. Zahr, Kilian M. Pohl, Allison J. Kwong, Edith V. Sullivan, Adolf Pfefferbaum
    International Journal of Molecular Sciences.2021; 22(9): 4953.     CrossRef
  • Cost-effectiveness of increased screening and treatment of chronic hepatitis C in Korea
    Do Young Kim, Gabriel Wong, Janet Lee, Myung Hwa Kim, Nathaniel Smith, Rob Blissett, Hyung Joon Kim
    Current Medical Research and Opinion.2020; 36(6): 993.     CrossRef
  • Cost‐effectiveness and health‐related outcomes of screening for hepatitis C in Korean population
    Kyung‐Ah Kim, Wankyo Chung, Hwa Young Choi, Moran Ki, Eun Sun Jang, Sook‐Hyang Jeong
    Liver International.2019; 39(1): 60.     CrossRef
  • International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting—From Noncirrhotic to Decompensated Disease and After Liver Transplantation
    Michael R. Charlton, Edward J. Gane, Aakash Shukla, Bekhbold Dashtseren, Davaadorj Duger, David H. Muljono, Diana A. Payawal, Ganbolor Jargalsaikhan, Hery D. Purnomo, Ian H. Cua, Irsan Hasan, Jose Sollano, Khin Maung Win, Laurentius A. Lesmana, Mohammad S
    Transplantation.2019; 103(4): 733.     CrossRef
  • Peripheral TNFα elevations in abstinent alcoholics are associated with hepatitis C infection
    Natalie M. Zahr, Kent E. Vrana
    PLOS ONE.2018; 13(2): e0191586.     CrossRef
  • Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea
    Do Young Kim, Kwang-Hyub Han, Byungyool Jun, Tae Hyun Kim, Sohee Park, Thomas Ward, Samantha Webster, Phil McEwan, Sheng-Nan Lu
    PLOS ONE.2017; 12(1): e0167770.     CrossRef
  • Hepatitis C diagnostic management gap in Pakistan—Clinicians’ knowledge impacting public health
    Fouzia Naseer, Ana Mukhtar, Altaf Ahmed, Afsheen Raza
    Journal of Public Health.2016; 24(4): 299.     CrossRef
  • Diagnosis and Management of Hepatitis C Virus Infection
    Ronita Mukherjee, Andrew Burns, Diane Rodden, Frances Chang, Manita Chaum, Nancy Garcia, Nikitha Bollipalli, Angelika Niemz
    SLAS Technology.2015; 20(5): 519.     CrossRef
  • 10,084 View
  • 59 Download
  • Crossref
Case Report
A case of leukemoid reaction in a patient with sarcomatous hepatocellular carcinoma
Hyun Phil Shin, Jung Won Jeon, Jae Jun Park, Jae Myung Cha, Kwang Ro Joo, Joung Il Lee, Gou Young Kim, So Young Kang
Korean J Hepatol 2011;17(3):226-228.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.226

A leukemoid reaction is defined as reactive leukocytosis exceeding 50,000/mm3, with a significant increase in early neutrophil precursors, and can be a paraneoplastic manifestation of various malignant tumors. A 71-year-old male patient complained of decreased appetite, fatigue, and abdominal fullness. He had a palpable, firm liver, and laboratory investigations suggested leukemoid reaction. Liver dynamic computed tomography revealed a hypervascular mass, and an ultrasound-guided fine-needle aspiration of the mass confirmed hepatocellular carcinoma (HCC) with a sarcomatoid component. The leukocyte count of the patient had increased to 147,800/mm3, and he died 10 days after admission. This is a rare case of leukemoid reaction in a patient with sarcomatous HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Pyrites: Leukocytosis
    Chinith Phauk, Angkeabos Nhip, Sam Lyvannak, Bun Sereyleak, Frank G. Keller, Jason Jarzembowski, Bruce Camitta
    Journal of Pediatric Hematology/Oncology.2024; 46(7): 388.     CrossRef
  • Leukomoid Reaction and Partial Exchange in an Infant with Pertussis
    Mehmet Nur Talay, Özhan Orhan, Asuman Demirbuğa
    International Journal of Infection.2024;[Epub]     CrossRef
  • Primary Liver Sarcomatoid Carcinoma: A Case Series and Literature Review
    Wei Ji, Yunlong Xing, Jinshu Ma, Zhuo Zhao, Hongqin Xu, Shuang Zheng, Wei Li, Xu Li
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 1117.     CrossRef
  • Severe digital ischemia coexists with thrombocytopenia in malignancy-associated antiphospholipid syndrome: A case report and review of literature
    Jia-Lei Chen, Xi Yu, Rong Luo, Ming Liu
    World Journal of Clinical Cases.2021; 9(36): 11457.     CrossRef
  • Paraneoplastic leukemoid reaction in a patient with sarcomatoid hepatocellular carcinoma: A case report
    Bo Hu, Xin-Ting Sang, Xiao-Bo Yang
    World Journal of Clinical Cases.2019; 7(11): 1330.     CrossRef
  • Néphropathie obstructive hyperuricémique liée à une hyperleucocytose réactionnelle au cours d’un carcinome hépato-cellulaire
    Laurys Boudin, Matthieu Patient, Emilie Roméo, Jean-Sébastien Bladé, Jean-Pierre de Jauréguiberry
    La Presse Médicale.2017; 46(2): 238.     CrossRef
  • Paraneoplastic Leukemoid Reaction in Solid Tumors
    Subhankar Chakraborty, Brent Keenportz, Suzette Woodward, Jay Anderson, David Colan
    American Journal of Clinical Oncology.2015; 38(3): 326.     CrossRef
  • Unusual computed tomography features of ruptured sarcomatous hepatocellular carcinoma
    Yuan Hung, Tsai-Yuan Hsieh, Hong-Wei Gao, Wei-Chou Chang, Wei-Kuo Chang
    Journal of the Chinese Medical Association.2014; 77(5): 265.     CrossRef
  • Leukemoid like reaction in a post CABG patient
    G Padmakumar, J Ravikrishnan, P Jayakumar, K Prasad
    Indian Journal of Anaesthesia.2014; 58(3): 315.     CrossRef
  • 9,691 View
  • 69 Download
  • Crossref